AMG 335 Expanded Access Program for IgG4-Related Disease
NCT06590051 · Status: AVAILABLE · Type: EXPANDED_ACCESS
Last updated 2024-09-19
Summary
Expanded access requests for AMG 335 may be considered for adult patients with a confirmed diagnosis of IgG4-related disease. To request access, use Responsible Party contact information provided in this record.
Interventions
- DRUG
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
MD · Amgen
Eligibility
- Sex
- Healthy Volunteers
- No
Timeline & Regulatory
More Related Trials
-
A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis
NCT06298552 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa
NCT06298565 ·Status: RECRUITING
-
A Study to Evaluate the Efficacy and Safety of IGIV-C in Symptomatic Subjects With Generalized Myasthenia Gravis
NCT02473952 ·Status: COMPLETED ·Phase: PHASE2
-
Pre-Approval Access for Efgartigimod PH20 SC in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
NCT04777734 ·Status: AVAILABLE
-
Study to Evaluate the Effect of XmAb®5871 on Disease Activity in Patients With IgG4-Related Disease (RD)
NCT02725476 ·Status: COMPLETED ·Phase: PHASE2
-
Ublituximab in Autoantibody Positive Immune Mediated Necrotizing Myopathy
NCT07103746 ·Status: RECRUITING ·Phase: PHASE2
-
A Study of Inebilizumab Efficacy and Safety in IgG4- Related Disease
NCT04540497 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
The Study of the Safety and Efficacy of Ampligen in Chronic Fatigue Syndrome
NCT00215800 ·Status: COMPLETED ·Phase: PHASE3
-
Treatment of Deficient Subclass or Anti-polysaccharide Antibody Response
NCT00522821 ·Status: COMPLETED ·Phase: PHASE4
-
Intravenous Immunoglobulin and Plasma Exchange in Myasthenia Gravis
NCT01179893 ·Status: COMPLETED ·Phase: PHASE4
-
Belimumab Treatment for IgG4-related Disease
NCT04660565 ·Status: UNKNOWN ·Phase: PHASE4
-
Open Label, Phase III Study of NABI-IGIV 10% [Immune Globulin Intravenous(Human), 10%] In Subjects With Primary Immune Deficiency Disorders (PIDD)
NCT00538915 ·Status: COMPLETED ·Phase: PHASE3
-
Personalized Immunotherapeutic for Antibiotic-resistant Infection
NCT02508584 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Add-on Intravenous Immunoglobulins in Early Myositis
NCT05832034 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2/PHASE3
-
A Study to Assess the Efficacy and Safety of IGIV-C in Patients With Myasthenia Gravis Exacerbations
NCT02413580 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Assess the Tolerability and Safety of Subcutaneously (SC) Administered Immunoglobulin G (IgG) With Varying Injection Conditions
NCT07025577 ·Status: COMPLETED ·Phase: PHASE1
-
Intravenous Immunoglobulin for Unverricht-Lundborg Disease.
NCT03351569 ·Status: UNKNOWN ·Phase: PHASE3
-
Treatment of IgG4-Related Disease With Revlimid and Rituximab
NCT02705638 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy and Safety of IGIV-C in Corticosteroid Dependent Patients With Generalized Myasthenia Gravis
NCT02473965 ·Status: COMPLETED ·Phase: PHASE2
-
A Study Evaluating the Safety and Efficacy of Rituximab in Combination With Glucocorticoids in Participants With Wegener's Granulomatosis or Microscopic Polyangitis
NCT02115997 ·Status: COMPLETED ·Phase: PHASE4
-
Randomized Study of Intravenous Immunoglobulin in Patients With Mild or Moderate Myasthenia Gravis
NCT00004682 ·Status: TERMINATED ·Phase: NA
-
An Observational Study of The Safety of MabThera/Rituxan (Rituximab) in Participants With Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis
NCT01613599 ·Status: COMPLETED
-
Open Label Two-Arm Study to Evaluate Rilzabrutinib in IgG4-Related Disease Participants
NCT04520451 ·Status: COMPLETED ·Phase: PHASE2
-
IVIG vs SCIG in CIDP
NCT05584631 ·Status: RECRUITING ·Phase: PHASE1
-
IVIG for Drug and Device Refractory Gastrointestinal Auto-Immune Neuropathy
NCT04208828 ·Status: RECRUITING